Document is current

Article History

Accepted: 5 July 2021

First Online: 21 July 2021

Declarations

:

: Not funded was used to conduct this study. GP is a research scholar from the Fonds de recherche du Québec–santé.

: ME reports personal fees from Novartis, Lilly Canada, TEVA Neurosciences, and Aralez, outside the submitted work. EL reports personal fees from Allergan, TEVA Neurosciences, Novartis, Aralez, Lilly Canada, Lundbeck, McKesson, and Medscape, outside the submitted work. GP reports no competing interests.

: This study was approved by the Institutional Review Board of the Montreal University Health Center. As this was a retrospective study, with fully anonymized data collection obtained during standard patient care, written informed consent was waived by the Institutional Review Board.

: Not applicable.

: Data are not publicly available in accordance with ethics approval given by the ethics board from the participating university. Interested investigators may submit inquiries to the corresponding author.

: Not applicable.

: ME, EL and GP made substantial contributions to the analysis or interpretation of data, drafted the work, substantively revised it, approved the final submission, and agree to be accountable for all aspects of the work.